Vaccines Investors: Angels and VC Firms

RaiseHunt currently lists 75 Vaccines investors.

Both. 17 are angel investors putting in their own money, and 58 are people making investment decisions at 19 firms.

The largest concentrations are in Boston, Cambridge and Paris.

Most list Seed and Series A among the rounds they take part in.

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

Longer than most first-time founders plan for. The work splits into building the list, running outreach, taking meetings, and closing, and each stage can stretch. Start before you need the money, not when the runway is short.

The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.

Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.

Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.